MerLion Pharmaceuticals GmbH

MerLion Pharmaceuticals GmbH is a bio-pharmaceutical company located in Berlin-Buch, Germany. Founded in 2000, the company specializes in the development of novel antibiotics to address the evolving threat of bacterial infections in humans and animals. Their focus encompasses non-clinical and clinical development, as well as active pharmaceutical ingredient and drug product development and manufacturing. The company's pipeline features the antibiotics finafloxacin and friulimicin. In its last investment round, MerLion Pharmaceuticals secured a $7.00M Series C investment on 11 October 2010, with backing from EDBI, VI Partners, Aravis, Rosetta Capital, Aurelia Private Equity GmbH, and HeidelbergCapital Private Equity. With a strong focus on addressing the critical need for new antibiotics, MerLion Pharmaceuticals presents a promising opportunity for investors interested in the biotechnology and pharmaceutical sectors.